News

Video

Researchers Say CAEL-101 is an Effective Amyloid Light Chain Amyloidosis Treatment

Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic about his new research surrounding CAEL-101, a treatment for patients living with amyloid light chain amyloidosis.

Pharmacy Times® interviewed Jason Valent, MD, of the Cleveland Clinic about his new research surrounding CAEL-101, a treatment for patients living with amyloid light chain amyloidosis, which was presented at the 62nd American Society of Hematology Annual Meeting & Exposition.

The full conversation can be found in the video above.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Magnified bone marrow biopsy showing plasma cells with irregular nuclei and multiple myeloma tumor cells infiltrating normal hematopoietic tissue
Image credit: Dr_Microbe | stock.adobe.com